Nevro’s 10kHz Therapy Earns UnitedHealthcare Coverage

Nevro Corp announced that UnitedHealthcare, the largest private health insurance company in the United States, will provide coverage for the company’s high-frequency 10 kHz Therapy for the treatment of PDN (Painful Diabetic Neuropathy) for dates of service on or after March 1, 2022. UnitedHealthcare is one of the businesses of UnitedHealth Group, a diversified health care company that provides coverage for more than 39 million commercial health care members.
 
“We believe this expeditious coverage decision from UnitedHealthcare following our submission to their medical policy team late last year is a major milestone and will facilitate access to Nevro’s proprietary 10 kHz Therapy for PDN patients,” stated D. Keith Grossman, Chairman, CEO, and president of Nevro. “As the only spinal cord stimulation system that is FDA approved to treat PDN, we believe we are uniquely positioned to treat the thousands of patients suffering from the debilitating effects of PDN with a proven non-drug option. We also believe our strong and growing body of published, peer-reviewed clinical and real-world data will be the basis for further coverage decisions by other major health plans in 2022 and beyond.”
 
Under its policy, UnitedHealthcare considers Nevro’s U.S. Food and Drug Administration (FDA) approved high-frequency spinal cord stimulator to be proven and medically necessary for the treatment of diabetic neuropathy when specified criteria are met.